Cancer is a widely recognized complication of transplantation, and the effects of various
immunosuppressive drugs on cancer risk remains controversial. This randomized trial
allocated 489 recipients of first cadaveric renal transplants to one of three groups:
Azathioprine and prednisolone, cyclosporine monotherapy, or cyclosporine monotherapy
followed by a switch to azathioprine and prednisolone after 3 months. Here, we report
cancer outcomes by non–skin cancer (including melanoma) and skin cancer (excluding …